Download PDF
Drug Res (Stuttg) 2015; 65(10): 526-531
DOI: 10.1055/s-0034-1390458
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Elevated Expression of Nrf-2 and ABCG2 Involved in Multi-drug Resistance of Lung Cancer SP Cells

B. Yang   *
1   Department of Thoracic Surgery, Chinese PLA General Hospital, Beijing, China
,
Y.-F. Ma   *
1   Department of Thoracic Surgery, Chinese PLA General Hospital, Beijing, China
,
Y. Liu
1   Department of Thoracic Surgery, Chinese PLA General Hospital, Beijing, China
› Author Affiliations
Further Information

Publication History

received 20 August 2014

accepted 29 August 2014

Publication Date:
04 November 2014 (online)

Also available at
    Permissions and Reprints

Abstract

Background: Over expression of ATP-binding cassette (ABC) transporter protein (ABCG2) in side population cells plays a crucial role in the chemotherapeutic drug efflux. Constitutive expression of redox sensing transcritption factor Nrf2 was shown to be involved in regulation of ABCG2 expression and chemoresistance. In the current study we made an attempt to characterize the lung adenocarcinoma SP cells.

Materials and Methods: We used FACs based Hoechst 33342 dye exclusion assay for purification of lung cancer SP cells. The sorted SP cells were subjected to drug resistance, sphere formation assays and gene expression analysis (Nrf2 and ABCG2).

Results: We have identified 2.9% of SP cells from lung cancer whose prevalence is significantly reduced to 0.3% upon treatment with verapamil. RT-PCR and western blot analysis revealed that Nrf2 and ABCG2 were highly expressed in lung cancer SP cells. Further, these SP cells are resistant to several chemotherapeutic drugs, self-renewal, and highly tumorigenic than non-SP cells.

Conclusions: Our data suggest that Nrf2-mediated ABCG2 over expression in lung adenocarcinoma SP cells might responsible for chemotherapy failure. Therefore, designing novel anticancer drugs that attenuates the Nrf2 and ABCG2 expression, makes SP cells more sensitive to chemotherapy and thus prevent the tumor relapse.

Key words

cancer stem-like cells - side-population cells - self-renewal - Nrf2 - chemoresistance

* These authors contributed equally to this work.


 

  • References

  • 1 Schoenhals M, Kassambara A, De Vos J et al. Embryonic stem cell markers expression in cancers. Biochem Biophys Res Commun 2009; 383: 157-162
    CrossrefPubMedGoogle Scholar
  • 2 Chiou SH, Wang ML, Chou YT et al. Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res 2010; 70: 10433-10444
    CrossrefPubMedGoogle Scholar
  • 3 Parkin DM, Bray F, Ferlay J et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108
    Google Scholar
  • 4 Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96
    CrossrefPubMedGoogle Scholar
  • 5 Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29
    CrossrefPubMedGoogle Scholar
  • 6 Salnikov AV, Gladkich J, Moldenhauer G et al. CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients. Int J Cancer 2010; 126: 950-958
    PubMedGoogle Scholar
  • 7 Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010; 29: 4741-4751
    CrossrefPubMedGoogle Scholar
  • 8 Ho MM, Ng AV, Lam S et al. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 2007; 67: 4827-4833
    CrossrefPubMedGoogle Scholar
  • 9 Das B, Tsuchida R, Malkin D et al. Hypoxia enhances tumor stemness by increasing the invasive and tumorigenic side population fraction. Stem Cells 2008; 26: 1818-1830
    CrossrefPubMedGoogle Scholar
  • 10 Ho MM, Ng AV, Lam S et al. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 2007; 67: 4827-4833
    CrossrefPubMedGoogle Scholar
  • 11 Singh A, Wu H, Zhang P et al. Expression of ABCG2 (BCRP), a Marker of Stem Cells, is regulated by Nrf2 in Cancer Cells That Confers Side Population and chemoresistance phenotype. Mol Cancer Ther 2010; 9: 2365-2376
    CrossrefPubMedGoogle Scholar
  • 12 He QZ, Luo XZ, Wang K et al. Isolation and characterization of cancer stem cells from high-grade serous ovarian carcinomas. Cell Physiol Biochem 2014; 33: 173-184
    CrossrefPubMedGoogle Scholar
  • 13 Shi Y, Fu X, Hua Y et al. The Side Population in Human Lung Cancer Cell Line NCI-H460 Is Enriched in Stem-Like Cancer Cells. PLoS One 2012; 7: e33358
    CrossrefPubMedGoogle Scholar
  • 14 Hirschmann-Jax C, Foster AE, Wulf GG et al. A distinct side population of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad USA 2004; 101: 14228-14233
    CrossrefPubMedGoogle Scholar
  • 15 Kondo T, Setoguchi T, Taga T. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci USA 2004; 101: 781-786
    CrossrefPubMedGoogle Scholar
  • 16 Gil J, Stembalska A, Pesz KA et al. Cancer stem cells: the theory and perspectives in cancer therapy. App Genet 2008; 49: 193-199
    PubMedGoogle Scholar
  • 17 Cho RW, Clarke FM. Recent advances in cancer stem cells. Current Opinion in Genetics & Development 2008; 18: 48-5
    CrossrefPubMedGoogle Scholar
  • 18 Patrawala L, Calhoun T, Schneider-Broussard R et al. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2− cancer cells are similarly tumorigenic. Cancer Research 2005; 65: 6207-6219
    CrossrefPubMedGoogle Scholar
  • 19 Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 2007; 47: 89-116
    CrossrefPubMedGoogle Scholar
  • 20 Bunting KD. ABC transporters as phenotypic markers and functional regulators of stem cells. Stem Cells 2002; 20: 11-20
    CrossrefPubMedGoogle Scholar
  • 21 Kopper L, Hajdu M. Tumor stem cells. Pathol Oncol Res 2004; 10: 69-73
    CrossrefPubMedGoogle Scholar
  • 22 Eramo A, Lotti F, Sette G et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008; 15: 504-514
    CrossrefPubMedGoogle Scholar
  • 23 Itoh K, Chiba T, Takahashi S et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 1997; 236: 313-322
    CrossrefPubMedGoogle Scholar
  • 24 Ramos-Gomez M, Kwak MK, Dolan PM et al. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc Natl Acad Sci USA 2001; 98: 3410-3415
    CrossrefPubMedGoogle Scholar
  • 25 Kwak MK, Kensler TW, Casero Jr RA. Induction of phase 2 enzymes by serum oxidized polyamines through activation of Nrf2. effect of the polyamine metabolite acrolein. Biochem Biophys Res Commun 2003; 305: 662-670
    CrossrefPubMedGoogle Scholar
  • 26 Kobayashi A, Kang MI, Okawa H et al. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 2004; 24: 7130-7139
    CrossrefPubMedGoogle Scholar
  • 27 Zhang DD, Lo SC, Cross JV et al. Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol Cell Biol 2004; 24: 10941-10953
    CrossrefPubMedGoogle Scholar
  • 28 Singh A, Misra V, Thimmulappa RK et al. Dysfunctional KEAP1-NRF2 interaction in non-smallcell lung cancer. PLoS Med 2006; 3: e420
    CrossrefPubMedGoogle Scholar
  • 29 Shibata T, Ohta T, Tong KI et al. Cancer related mutations in NRF2 impair its recognition byKeap1-Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci USA 2008; 105: 13568-13573
    CrossrefPubMedGoogle Scholar